AI-Native Scoping Reviews & Evidence Mapping

Snuffbox AVF emerges as a clinically credible distal-first hemodialysis access strategy, offering patency broadly comparable to wrist radiocephalic fistulas while preserving future access options. The full SAIMSARA evidence map is worth reading because it separates durable signals from selection-dependent outcomes, complications, reintervention needs, vessel-diameter thresholds, and long-term uncertainty across the available snuffbox fistula literature.

Cannabis is no longer a peripheral cardiovascular question: this evidence map shows repeated risk signals for MI, stroke, arrhythmias, perioperative events, vascular stiffness, and acute THC-driven hemodynamic stress, while also separating mixed or null findings for hypertension and atrial fibrillation. The full SAIMSARA evidence map is worth reading because it organizes 259 original studies into clinically usable risk patterns across daily use, CUD, medical cannabis, CBD, synthetic cannabinoids, pregnancy, young ACS patients, surgery, and vulnerable cardiovascular populations.

AI clinical scribes can reduce documentation burden, but this evidence map shows why they are not yet safe as autonomous note-writers: hallucinations, omissions, acoustic failures, EHR friction, consent gaps, and medicolegal uncertainty remain central limitations. The full SAIMSARA evidence map gives a structured, reference-linked view of where ambient AI documentation works, where it fails, and what clinicians, vendors, and health systems must verify before scaling it.

Medical machine translation may look fluent, but this review shows where it still breaks: semantic precision, cultural nuance, audience adaptation, and high-stakes clinical reliability. The full read is worth it because it separates the real strengths of MT in constrained tasks from the specific failure modes that still make expert human oversight essential.

This review shows that the strongest medication signal in AAA is not true aneurysm-shrinking therapy, but better survival: statins and antiplatelet treatment repeatedly track with lower long-term mortality, while most putative growth-modifying drugs still rest on mixed or observational evidence. It maps where medical AAA care is already actionable today, where metformin and other candidates remain uncertain, and which pharmacologic strategies may genuinely change aneurysm biology rather than just cardiovascular risk.

PAD is not failing for lack of options — it is failing because the right options are too often used in isolation, too late, or not at all. This review shows where the strongest treatment signals truly are, from rivaroxaban-plus-aspirin and exercise therapy to IVUS-guided revascularization, and why real progress depends on combining them into one strategy.

Popliteal venous aneurysm is rare, but the mapped evidence shows why it matters: recurrent PE, saccular morphology, thrombus burden, and size thresholds above 20–25 mm repeatedly point toward clinically relevant embolic risk. The full SAIMSARA evidence map gives humans and AI agents a structured, reference-linked view of presentation patterns, operative strategies, patency outcomes, anticoagulation limits, and unresolved thresholds for intervention.

Personalized healthcare is no longer just a promise of precision medicine — this review shows where it is already becoming clinically real, from AI prediction and pharmacogenomics to wearable monitoring and tailored care pathways. Across more than 1,300 original studies, the paper maps which personalized strategies are truly improving diagnosis, chronic disease control, and care delivery — and where the field still risks failing on fairness, infrastructure, and real-world implementation.

Combat sports are not only contests of power, technique, and mental resilience — they are also defined by a dangerous hidden physiology of rapid weight loss, dehydration, concussion, and cumulative trauma. This review maps where performance advantage ends and measurable athlete harm begins, highlighting why modern combat-sport medicine must integrate weight-cut monitoring, concussion protocols, ringside screening, and female-athlete surveillance.